Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC

Carol Sze Ki Leung; Benoit J Van den Eynde

doi:10.1016/j.ccell.2022.08.002

Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC

Cancer Cell. 2022 Sep 12;40(9):903-905. doi: 10.1016/j.ccell.2022.08.002. Epub 2022 Aug 25.

Authors

Carol Sze Ki Leung¹, Benoit J Van den Eynde²

Affiliations

¹ Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK. Electronic address: carol.leung@ludwig.ox.ac.uk.
² Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK; Ludwig Institute for Cancer Research, WELBIO, de Duve Institute, UCLouvain, Brussels, Belgium. Electronic address: benoit.vandeneynde@ludwig.ox.ac.uk.

PMID: 36027917
DOI: 10.1016/j.ccell.2022.08.002

Abstract

In this issue of Cancer Cell, Awad et al. report a phase 1b clinical trial combining a personalized vaccine NEO-PV-01 with chemotherapy and anti-PD-1 pembrolizumab in first-line metastatic non-squamous NSCLC. They demonstrate that this treatment regimen was well tolerated and induced neoantigen-specific CD4⁺ T cell responses with effector phenotype.

Publication types

Introductory Journal Article
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / pathology
Clinical Trials, Phase I as Topic
Humans
Lung Neoplasms* / pathology
Vaccination